[Post-menopausal osteoporosis: Up-to-date]

K Briot; C Roux

doi:10.1016/j.revmed.2015.11.008

[Post-menopausal osteoporosis: Up-to-date]

Rev Med Interne. 2016 Mar;37(3):195-200. doi: 10.1016/j.revmed.2015.11.008. Epub 2015 Dec 23.

[Article in French]

Authors

K Briot¹, C Roux²

Affiliations

¹ Service de rhumatologie, hôpital Cochin, université Paris-Descartes, Inserm U 1153, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
² Service de rhumatologie, hôpital Cochin, université Paris-Descartes, Inserm U 1153, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. Electronic address: christian.roux@aphp.fr.

PMID: 26723850
DOI: 10.1016/j.revmed.2015.11.008

Abstract

Patients with a high risk of fragility fractures, and those with recent fractures, must receive the highest priority for anti-osteoporotic treatment, because of the consequences of some of these fractures (hip, vertebrae, pelvis, humerus). Both non pharmacological and pharmacological treatments must be used. The duration of the treatment is based on the assessment of fracture risk.

Keywords: Anti-osteoporotic treatment; Fracture; Ostéoporose post-ménopausique; Post-menopausal osteoporosis; Traitement anti-ostéoporotique.

MeSH terms

Bone Density Conservation Agents / therapeutic use
Endocrinology / trends
Female
Humans
Osteoporosis, Postmenopausal / complications
Osteoporosis, Postmenopausal / therapy*
Osteoporotic Fractures / prevention & control
Patient Selection
Risk Factors

Substances

Bone Density Conservation Agents